APO Research
Talk to an analyst

APO RESEARCH · REPORT

Living Biological Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Living Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

16 January 2026198 pages

Choose your research edition.

Industry ResearchLiving Biological Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Living Biological Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Living Biological Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Living Biological Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Living Biological Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Living Biological Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Living Biological Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Living Biological Drugs include Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics, Infant Bacterial Therapeutics, Osel, Takeda, AOBiome and Synlogic, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Living Biological Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Living Biological Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Living Biological Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Living Biological Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Living Biological Drugs Segment by Company

Ardeypharman

Miyarisan Pharmaceutical

Ferring Pharmaceuticals

Seres Therapeutics

Infant Bacterial Therapeutics

Osel

Takeda

AOBiome

Synlogic

Finch Therapeutics

Capsugel

Jeneil Biotech

UAS Labs

Biose

Cerbios-Pharma

Inpac Probiotics

NIZO

Winclove Probiotics

BJP Laboratories

Luina Bio

List Labs

MatriSys Bioscience

Living Biological Drugs Segment by Type

Single Strain

Multi Strain

Co-Culture

Living Biological Drugs Segment by Application

Digestive System

Urinary System

Skin System

Living Biological Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Living Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Living Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Living Biological Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Living Biological Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Living Biological Drugs industry.

Chapter 3: Detailed analysis of Living Biological Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Living Biological Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Living Biological Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Single Strain Table 3. Key Players of Multi Strain Table 4. Key Players of Co-Culture Table 4. Global Living Biological Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Digestive System Table 6. Key Players of Urinary System Table 7. Key Players of Skin System Table 8. Global Living Biological Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Living Biological Drugs Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Living Biological Drugs Market Share by Region (2021-2026) Table 11. Global Living Biological Drugs Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Living Biological Drugs Market Share by Region (2027-2032) Table 13. Living Biological Drugs Industry Trends Table 14. Living Biological Drugs Industry Drivers Table 15. Living Biological Drugs Industry Opportunities and Challenges Table 16. Living Biological Drugs Industry Restraints Table 17. Global Living Biological Drugs Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Living Biological Drugs Revenue Market Share by Company (2021-2026) Table 19. Global Living Biological Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Living Biological Drugs Key Company Head Office and Area Served Table 21. Global Living Biological Drugs Company, Product Type & Application Table 22. Global Living Biological Drugs Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Living Biological Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Living Biological Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Living Biological Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Living Biological Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Living Biological Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Living Biological Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Living Biological Drugs Revenue Market Share by Application (2027-2032) Table 35. Ardeypharman Company Information Table 36. Ardeypharman Business Overview Table 37. Ardeypharman Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Ardeypharman Living Biological Drugs Product Portfolio Table 39. Ardeypharman Recent Development Table 40. Miyarisan Pharmaceutical Company Information Table 41. Miyarisan Pharmaceutical Business Overview Table 42. Miyarisan Pharmaceutical Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio Table 44. Miyarisan Pharmaceutical Recent Development Table 45. Ferring Pharmaceuticals Company Information Table 46. Ferring Pharmaceuticals Business Overview Table 47. Ferring Pharmaceuticals Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Ferring Pharmaceuticals Living Biological Drugs Product Portfolio Table 49. Ferring Pharmaceuticals Recent Development Table 50. Seres Therapeutics Company Information Table 51. Seres Therapeutics Business Overview Table 52. Seres Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Seres Therapeutics Living Biological Drugs Product Portfolio Table 54. Seres Therapeutics Recent Development Table 55. Infant Bacterial Therapeutics Company Information Table 56. Infant Bacterial Therapeutics Business Overview Table 57. Infant Bacterial Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio Table 59. Infant Bacterial Therapeutics Recent Development Table 60. Osel Company Information Table 61. Osel Business Overview Table 62. Osel Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Osel Living Biological Drugs Product Portfolio Table 64. Osel Recent Development Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Takeda Living Biological Drugs Product Portfolio Table 69. Takeda Recent Development Table 70. AOBiome Company Information Table 71. AOBiome Business Overview Table 72. AOBiome Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. AOBiome Living Biological Drugs Product Portfolio Table 74. AOBiome Recent Development Table 75. Synlogic Company Information Table 76. Synlogic Business Overview Table 77. Synlogic Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Synlogic Living Biological Drugs Product Portfolio Table 79. Synlogic Recent Development Table 80. Finch Therapeutics Company Information Table 81. Finch Therapeutics Business Overview Table 82. Finch Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Finch Therapeutics Living Biological Drugs Product Portfolio Table 84. Finch Therapeutics Recent Development Table 85. Capsugel Company Information Table 86. Capsugel Business Overview Table 87. Capsugel Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Capsugel Living Biological Drugs Product Portfolio Table 89. Capsugel Recent Development Table 90. Jeneil Biotech Company Information Table 91. Jeneil Biotech Business Overview Table 92. Jeneil Biotech Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Jeneil Biotech Living Biological Drugs Product Portfolio Table 94. Jeneil Biotech Recent Development Table 95. UAS Labs Company Information Table 96. UAS Labs Business Overview Table 97. UAS Labs Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. UAS Labs Living Biological Drugs Product Portfolio Table 99. UAS Labs Recent Development Table 100. Biose Company Information Table 101. Biose Business Overview Table 102. Biose Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Biose Living Biological Drugs Product Portfolio Table 104. Biose Recent Development Table 105. Cerbios-Pharma Company Information Table 106. Cerbios-Pharma Business Overview Table 107. Cerbios-Pharma Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Cerbios-Pharma Living Biological Drugs Product Portfolio Table 109. Cerbios-Pharma Recent Development Table 110. Inpac Probiotics Company Information Table 111. Inpac Probiotics Business Overview Table 112. Inpac Probiotics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. Inpac Probiotics Living Biological Drugs Product Portfolio Table 114. Inpac Probiotics Recent Development Table 115. NIZO Company Information Table 116. NIZO Business Overview Table 117. NIZO Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 118. NIZO Living Biological Drugs Product Portfolio Table 119. NIZO Recent Development Table 120. Winclove Probiotics Company Information Table 121. Winclove Probiotics Business Overview Table 122. Winclove Probiotics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 123. Winclove Probiotics Living Biological Drugs Product Portfolio Table 124. Winclove Probiotics Recent Development Table 125. BJP Laboratories Company Information Table 126. BJP Laboratories Business Overview Table 127. BJP Laboratories Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 128. BJP Laboratories Living Biological Drugs Product Portfolio Table 129. BJP Laboratories Recent Development Table 130. Luina Bio Company Information Table 131. Luina Bio Business Overview Table 132. Luina Bio Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 133. Luina Bio Living Biological Drugs Product Portfolio Table 134. Luina Bio Recent Development Table 135. List Labs Company Information Table 136. List Labs Business Overview Table 137. List Labs Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 138. List Labs Living Biological Drugs Product Portfolio Table 139. List Labs Recent Development Table 140. MatriSys Bioscience Company Information Table 141. MatriSys Bioscience Business Overview Table 142. MatriSys Bioscience Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 143. MatriSys Bioscience Living Biological Drugs Product Portfolio Table 144. MatriSys Bioscience Recent Development Table 145. North America Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 146. North America Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 147. North America Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 148. North America Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 149. North America Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Living Biological Drugs Market Size by Country (2021-2026) Table 151. North America Living Biological Drugs Market Size by Country (2027-2032) Table 152. Europe Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 153. Europe Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 154. Europe Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 155. Europe Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 156. Europe Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe Living Biological Drugs Market Size by Country (2021-2026) Table 158. Europe Living Biological Drugs Market Size by Country (2027-2032) Table 159. China Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 160. China Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 161. China Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 162. China Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 163. Asia Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 164. Asia Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 165. Asia Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 166. Asia Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 167. Asia Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia Living Biological Drugs Market Size by Country (2021-2026) Table 169. Asia Living Biological Drugs Market Size by Country (2027-2032) Table 170. South America, Middle East & Africa Living Biological Drugs Market Size by Type (2021-2026) & (US$ Million) Table 171. South America, Middle East & Africa Living Biological Drugs Market Size by Type (2027-2032) & (US$ Million) Table 172. South America, Middle East & Africa Living Biological Drugs Market Size by Application (2021-2026) & (US$ Million) Table 173. South America, Middle East & Africa Living Biological Drugs Market Size by Application (2027-2032) & (US$ Million) Table 174. South America, Middle East & Africa Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. South America, Middle East & Africa Living Biological Drugs Market Size by Country (2021-2026) Table 176. South America, Middle East & Africa Living Biological Drugs Market Size by Country (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Living Biological Drugs Product Image Figure 2. Global Living Biological Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Living Biological Drugs Market Share by Type: 2025 VS 2032 Figure 4. Single Strain Image Figure 5. Multi Strain Image Figure 6. Co-Culture Image Figure 7. Global Living Biological Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Living Biological Drugs Market Share by Application: 2025 VS 2032 Figure 9. Digestive System Image Figure 10. Urinary System Image Figure 11. Skin System Image Figure 12. Global Living Biological Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 14. Global Living Biological Drugs Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Living Biological Drugs Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Living Biological Drugs Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Living Biological Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Living Biological Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Living Biological Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Living Biological Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 24. North America Living Biological Drugs Market Share by Type (2021-2032) Figure 25. North America Living Biological Drugs Market Share by Application (2021-2032) Figure 26. North America Living Biological Drugs Market Share by Country (2021-2032) Figure 27. United States Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 28. Canada Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Europe Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Europe Living Biological Drugs Market Share by Type (2021-2032) Figure 32. Europe Living Biological Drugs Market Share by Application (2021-2032) Figure 33. Europe Living Biological Drugs Market Share by Country (2021-2032) Figure 34. Germany Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 35. France Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 37. Italy Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 38. Russia Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 40. China Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 41. China Living Biological Drugs Market Share by Type (2021-2032) Figure 42. China Living Biological Drugs Market Share by Application (2021-2032) Figure 43. Asia Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 44. Asia Living Biological Drugs Market Share by Type (2021-2032) Figure 45. Asia Living Biological Drugs Market Share by Application (2021-2032) Figure 46. Asia Living Biological Drugs Market Share by Country (2021-2032) Figure 47. Japan Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 51. India Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Australia Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Living Biological Drugs Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Living Biological Drugs Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Living Biological Drugs Market Share by Country (2021-2032) Figure 57. Brazil Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 62. UAE Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Chile Living Biological Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Single Strain
  • Multi Strain
  • Co-Culture
Applications
  • Digestive System
  • Urinary System
  • Skin System
Companies covered
  • Ardeypharman
  • Miyarisan Pharmaceutical
  • Ferring Pharmaceuticals
  • Seres Therapeutics
  • Infant Bacterial Therapeutics
  • Osel
  • Takeda
  • AOBiome
  • Synlogic
  • Finch Therapeutics
  • Capsugel
  • Jeneil Biotech
  • UAS Labs
  • Biose
  • Cerbios-Pharma
  • Inpac Probiotics
  • NIZO
  • Winclove Probiotics
  • BJP Laboratories
  • Luina Bio
  • List Labs
  • MatriSys Bioscience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Living Biological Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Single Strain
  5. 1.2.3 Multi Strain
  6. 1.2.4 Co-Culture
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Living Biological Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Digestive System
  10. 1.3.3 Urinary System
  11. 1.3.4 Skin System
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Living Biological Drugs Growth Trends by Region
  14. 1.5.1 Global Living Biological Drugs Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Living Biological Drugs Market Size by Region (2021-2026)
  16. 1.5.3 Living Biological Drugs Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Living Biological Drugs Market Dynamics
  1. 2.1 Living Biological Drugs Industry Trends
  2. 2.2 Living Biological Drugs Industry Drivers
  3. 2.3 Living Biological Drugs Industry Opportunities and Challenges
  4. 2.4 Living Biological Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Living Biological Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Living Biological Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Living Biological Drugs Key Company Head office and Area Served
  4. 3.4 Global Living Biological Drugs Company, Product Type & Application
  5. 3.5 Global Living Biological Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Living Biological Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Living Biological Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Living Biological Drugs Tier 1, Tier 2, and Tier 3
4 Living Biological Drugs Market by Type
  1. 4.1 Global Living Biological Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Living Biological Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Living Biological Drugs Market Size Share by Type (2021-2032)
5 Living Biological Drugs Market by Application
  1. 5.1 Global Living Biological Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Living Biological Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Living Biological Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Ardeypharman
  2. 6.1.1 Ardeypharman Company Information
  3. 6.1.2 Ardeypharman Business Overview
  4. 6.1.3 Ardeypharman Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Ardeypharman Living Biological Drugs Product Portfolio
  6. 6.1.5 Ardeypharman Recent Developments
  7. 6.2 Miyarisan Pharmaceutical
  8. 6.2.1 Miyarisan Pharmaceutical Company Information
  9. 6.2.2 Miyarisan Pharmaceutical Business Overview
  10. 6.2.3 Miyarisan Pharmaceutical Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio
  12. 6.2.5 Miyarisan Pharmaceutical Recent Developments
  13. 6.3 Ferring Pharmaceuticals
  14. 6.3.1 Ferring Pharmaceuticals Company Information
  15. 6.3.2 Ferring Pharmaceuticals Business Overview
  16. 6.3.3 Ferring Pharmaceuticals Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Ferring Pharmaceuticals Living Biological Drugs Product Portfolio
  18. 6.3.5 Ferring Pharmaceuticals Recent Developments
  19. 6.4 Seres Therapeutics
  20. 6.4.1 Seres Therapeutics Company Information
  21. 6.4.2 Seres Therapeutics Business Overview
  22. 6.4.3 Seres Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Seres Therapeutics Living Biological Drugs Product Portfolio
  24. 6.4.5 Seres Therapeutics Recent Developments
  25. 6.5 Infant Bacterial Therapeutics
  26. 6.5.1 Infant Bacterial Therapeutics Company Information
  27. 6.5.2 Infant Bacterial Therapeutics Business Overview
  28. 6.5.3 Infant Bacterial Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio
  30. 6.5.5 Infant Bacterial Therapeutics Recent Developments
  31. 6.6 Osel
  32. 6.6.1 Osel Company Information
  33. 6.6.2 Osel Business Overview
  34. 6.6.3 Osel Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Osel Living Biological Drugs Product Portfolio
  36. 6.6.5 Osel Recent Developments
  37. 6.7 Takeda
  38. 6.7.1 Takeda Company Information
  39. 6.7.2 Takeda Business Overview
  40. 6.7.3 Takeda Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Takeda Living Biological Drugs Product Portfolio
  42. 6.7.5 Takeda Recent Developments
  43. 6.8 AOBiome
  44. 6.8.1 AOBiome Company Information
  45. 6.8.2 AOBiome Business Overview
  46. 6.8.3 AOBiome Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 AOBiome Living Biological Drugs Product Portfolio
  48. 6.8.5 AOBiome Recent Developments
  49. 6.9 Synlogic
  50. 6.9.1 Synlogic Company Information
  51. 6.9.2 Synlogic Business Overview
  52. 6.9.3 Synlogic Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Synlogic Living Biological Drugs Product Portfolio
  54. 6.9.5 Synlogic Recent Developments
  55. 6.10 Finch Therapeutics
  56. 6.10.1 Finch Therapeutics Company Information
  57. 6.10.2 Finch Therapeutics Business Overview
  58. 6.10.3 Finch Therapeutics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Finch Therapeutics Living Biological Drugs Product Portfolio
  60. 6.10.5 Finch Therapeutics Recent Developments
  61. 6.11 Capsugel
  62. 6.11.1 Capsugel Company Information
  63. 6.11.2 Capsugel Business Overview
  64. 6.11.3 Capsugel Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Capsugel Living Biological Drugs Product Portfolio
  66. 6.11.5 Capsugel Recent Developments
  67. 6.12 Jeneil Biotech
  68. 6.12.1 Jeneil Biotech Company Information
  69. 6.12.2 Jeneil Biotech Business Overview
  70. 6.12.3 Jeneil Biotech Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Jeneil Biotech Living Biological Drugs Product Portfolio
  72. 6.12.5 Jeneil Biotech Recent Developments
  73. 6.13 UAS Labs
  74. 6.13.1 UAS Labs Company Information
  75. 6.13.2 UAS Labs Business Overview
  76. 6.13.3 UAS Labs Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 UAS Labs Living Biological Drugs Product Portfolio
  78. 6.13.5 UAS Labs Recent Developments
  79. 6.14 Biose
  80. 6.14.1 Biose Company Information
  81. 6.14.2 Biose Business Overview
  82. 6.14.3 Biose Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Biose Living Biological Drugs Product Portfolio
  84. 6.14.5 Biose Recent Developments
  85. 6.15 Cerbios-Pharma
  86. 6.15.1 Cerbios-Pharma Company Information
  87. 6.15.2 Cerbios-Pharma Business Overview
  88. 6.15.3 Cerbios-Pharma Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Cerbios-Pharma Living Biological Drugs Product Portfolio
  90. 6.15.5 Cerbios-Pharma Recent Developments
  91. 6.16 Inpac Probiotics
  92. 6.16.1 Inpac Probiotics Company Information
  93. 6.16.2 Inpac Probiotics Business Overview
  94. 6.16.3 Inpac Probiotics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Inpac Probiotics Living Biological Drugs Product Portfolio
  96. 6.16.5 Inpac Probiotics Recent Developments
  97. 6.17 NIZO
  98. 6.17.1 NIZO Company Information
  99. 6.17.2 NIZO Business Overview
  100. 6.17.3 NIZO Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 NIZO Living Biological Drugs Product Portfolio
  102. 6.17.5 NIZO Recent Developments
  103. 6.18 Winclove Probiotics
  104. 6.18.1 Winclove Probiotics Company Information
  105. 6.18.2 Winclove Probiotics Business Overview
  106. 6.18.3 Winclove Probiotics Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Winclove Probiotics Living Biological Drugs Product Portfolio
  108. 6.18.5 Winclove Probiotics Recent Developments
  109. 6.19 BJP Laboratories
  110. 6.19.1 BJP Laboratories Company Information
  111. 6.19.2 BJP Laboratories Business Overview
  112. 6.19.3 BJP Laboratories Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 BJP Laboratories Living Biological Drugs Product Portfolio
  114. 6.19.5 BJP Laboratories Recent Developments
  115. 6.20 Luina Bio
  116. 6.20.1 Luina Bio Company Information
  117. 6.20.2 Luina Bio Business Overview
  118. 6.20.3 Luina Bio Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Luina Bio Living Biological Drugs Product Portfolio
  120. 6.20.5 Luina Bio Recent Developments
  121. 6.21 List Labs
  122. 6.21.1 List Labs Company Information
  123. 6.21.2 List Labs Business Overview
  124. 6.21.3 List Labs Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 List Labs Living Biological Drugs Product Portfolio
  126. 6.21.5 List Labs Recent Developments
  127. 6.22 MatriSys Bioscience
  128. 6.22.1 MatriSys Bioscience Company Information
  129. 6.22.2 MatriSys Bioscience Business Overview
  130. 6.22.3 MatriSys Bioscience Living Biological Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 MatriSys Bioscience Living Biological Drugs Product Portfolio
  132. 6.22.5 MatriSys Bioscience Recent Developments
7 North America
  1. 7.1 North America Living Biological Drugs Market Size (2021-2032)
  2. 7.2 North America Living Biological Drugs Market Size by Type
  3. 7.2.1 North America Living Biological Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Living Biological Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Living Biological Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Living Biological Drugs Market Size by Application
  7. 7.3.1 North America Living Biological Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Living Biological Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Living Biological Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Living Biological Drugs Market Size by Country
  11. 7.4.1 North America Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Living Biological Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Living Biological Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Living Biological Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Living Biological Drugs Market Size (2021-2032)
  2. 8.2 Europe Living Biological Drugs Market Size by Type
  3. 8.2.1 Europe Living Biological Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Living Biological Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Living Biological Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Living Biological Drugs Market Size by Application
  7. 8.3.1 Europe Living Biological Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Living Biological Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Living Biological Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Living Biological Drugs Market Size by Country
  11. 8.4.1 Europe Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Living Biological Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Living Biological Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Living Biological Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Living Biological Drugs Market Size (2021-2032)
  2. 9.2 China Living Biological Drugs Market Size by Type
  3. 9.2.1 China Living Biological Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Living Biological Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Living Biological Drugs Market Share by Type (2021-2032)
  6. 9.3 China Living Biological Drugs Market Size by Application
  7. 9.3.1 China Living Biological Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Living Biological Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Living Biological Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Living Biological Drugs Market Size (2021-2032)
  2. 10.2 Asia Living Biological Drugs Market Size by Type
  3. 10.2.1 Asia Living Biological Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Living Biological Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Living Biological Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Living Biological Drugs Market Size by Application
  7. 10.3.1 Asia Living Biological Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Living Biological Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Living Biological Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Living Biological Drugs Market Size by Country
  11. 10.4.1 Asia Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Living Biological Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Living Biological Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Living Biological Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Living Biological Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Living Biological Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Living Biological Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Living Biological Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Living Biological Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Living Biological Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Living Biological Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Living Biological Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Living Biological Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Living Biological Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Living Biological Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Living Biological Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Living Biological Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Living Biological Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst